title: Gastroduodenal tolerability of lumiracoxib vs placebo and naproxen: a pilot endoscopic study in healthy male subjects.
abstract: BACKGROUND
  Lumiracoxib (Prexige) is a cyclooxygenase-2 (COX-2) selective inhibitor.
  
  
  OBJECTIVE
  To compare the gastroduodenal tolerability of lumiracoxib with placebo and naproxen in a randomized, parallel-group, double-blind study.
  
  
  METHODS
  : Sixty-five healthy male subjects were randomized to receive 8 days' dosing with lumiracoxib 200 mg twice daily (b.d.) (n = 21), placebo (n = 22) or naproxen 500 mg b.d. (n = 22). Endoscopic evaluations of gastric and duodenal mucosae were conducted at baseline and after 8 days' dosing. Serum was assayed for ex-vivo concentrations of thromboxane B2 (TxB2) to determine cyclooxygenase-1 (COX-1) inhibitory activity.
  
  
  RESULTS
  Sixty subjects (20 per group) completed the study. No gastroduodenal erosions were observed in subjects receiving lumiracoxib. Thirteen subjects receiving naproxen developed duodenal erosions. At the gastric site, one subject in each of the naproxen and placebo groups had erosions; one subject receiving naproxen also developed a small asymptomatic gastric ulcer. Gastrointestinal adverse events accounted for 42.3% of all adverse events, occurring in 3/21, 4/22 and 6/22 of the lumiracoxib, placebo and naproxen groups, respectively. TxB2 levels were similar for patients receiving placebo or lumiracoxib, but were reduced by > 95% in patients receiving naproxen, compared with placebo.
  
  
  CONCLUSIONS
  Multiple doses of lumiracoxib resulted in gastroduodenal tolerability similar to placebo and superior to naproxen.
authors.affiliation: Novartis Pharma AG, Basel, Switzerland. christiane.rordorf@pharma.novartis.com
authors.forename: C
authors.initials: C
authors.lastname: Rordorf
authors.forename: N
authors.initials: N
authors.lastname: Kellett
authors.forename: S
authors.initials: S
authors.lastname: Mair
authors.forename: M
authors.initials: M
authors.lastname: Ford
authors.forename: S
authors.initials: S
authors.lastname: Milosavljev
authors.forename: J
authors.initials: J
authors.lastname: Branson
authors.forename: G
authors.initials: G
authors.lastname: Scott
mesh_terms: D000293:Adolescent; D000328:Adult; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects* / Q000493:pharmacokinetics; D004008:Diclofenac / Q000031:analogs & derivatives; D004311:Double-Blind Method; D016099:Endoscopy, Gastrointestinal; D005767:Gastrointestinal Diseases / Q000139:chemically induced*; D006801:Humans; D007413:Intestinal Mucosa; D007527:Isoenzymes / Q000037:antagonists & inhibitors*; D008297:Male; D008565:Membrane Proteins; D008875:Middle Aged; D009288:Naproxen / Q000009:adverse effects* / Q000493:pharmacokinetics; D009930:Organic Chemicals / Q000009:adverse effects* / Q000493:pharmacokinetics; D010865:Pilot Projects; D011451:Prostaglandin-Endoperoxide Synthases; D013931:Thromboxanes / Q000097:blood
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D008565:Membrane Proteins; D009930:Organic Chemicals; D013931:Thromboxanes; D004008:Diclofenac; D009288:Naproxen; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; C473384:lumiracoxib